neonat
infect
continu
caus
morbid
mortal
infant
among
approxim
infant
follow
nation
incid
rate
earlyonset
sepsi
eo
infect
within
day
life
case
per
live
birth
twothird
frequent
isol
organ
associ
group
b
streptococcu
gb
escherichia
coli
although
term
infant
treat
newborn
nurseri
infect
infant
requir
intens
care
manag
surviv
beyond
day
life
episod
lateonset
sepsi
lo
infect
day
life
overal
mortal
rate
infect
infant
newborn
infant
increas
risk
infect
rel
immunodefici
may
due
decreas
passag
matern
antibodi
preterm
infant
immatur
immun
system
gener
innat
immun
function
infant
impair
decreas
product
inflammatori
marker
interleukin
tumor
necrosi
factor
decreas
dendrit
neutrophil
function
adapt
immun
system
less
optim
decreas
cytotox
function
decreas
cell
mediat
immun
delay
lack
isotyp
switch
complement
import
opson
bacteri
kill
term
infant
complement
level
approxim
half
compar
adult
taken
togeth
predispos
infant
sever
prolong
recurr
infect
associ
bacteri
viral
fungal
infect
suspect
sepsi
presum
infect
rule
sepsi
remain
common
diagnos
nurseri
intens
care
unit
nicu
american
academi
pediatr
aap
committe
fetu
newborn
publish
clinic
report
extens
discuss
clinic
relev
challeng
identifi
newborn
sign
sepsi
high
likelihood
eo
requir
antimicrobi
regimen
identifi
healthyappear
newborn
high
likelihood
eo
requir
antimicrobi
regimen
committe
conclud
although
guidelin
evidencebas
may
modifi
clinic
judgment
provid
primari
reason
clinic
present
neonat
infect
may
subtl
nonspecif
may
overlap
noninfecti
caus
mani
clinician
empir
start
broad
spectrum
antimicrobi
regimen
infant
consid
risk
sepsi
antibiot
occasion
continu
despit
neg
blood
cultur
practic
may
detriment
infant
increas
risk
invas
fungal
infect
necrot
enterocol
nec
death
increas
pressur
select
multidrugresist
organ
even
risk
lo
purpos
articl
provid
evidencebas
practic
approach
diagnosi
manag
prevent
neonat
infect
time
transmiss
one
factor
contribut
caus
neonat
infect
differ
pathogen
may
acquir
pregnanc
prenat
deliveri
perinat
deliveri
postnat
tabl
show
differ
period
transmiss
variou
neonat
pathogen
introduct
new
molecularbas
assay
quantit
realtim
polymeras
chain
reaction
pcr
pave
way
increas
recognit
respiratori
viral
infect
contribut
rule
sepsi
lateonset
infect
tabl
includ
respiratori
viral
infect
coronaviru
enteroviru
human
metapneumoviru
influenza
parainfluenza
viru
respiratori
syncyti
viru
rsv
rhinoviru
possibl
caus
postnat
infect
infant
clinic
present
earlyonset
infect
eo
arbitrarili
defin
infect
within
first
day
life
common
organ
associ
eo
includ
gb
e
coli
gener
risk
bacteri
infect
healthyappear
newborn
remain
rel
low
common
clinic
find
includ
hypoglycemia
mgdl
hypothermia
c
follow
hyperglycemia
mgdl
apnea
edward
baker
summar
newborn
infant
sepsi
manifest
similar
clinic
sign
mening
includ
hyperthermia
hypothermia
respiratori
distress
anorexia
vomit
jaundic
lethargi
hypotens
may
frequent
found
infant
sepsi
wherea
irrit
convuls
bulg
full
fontanel
found
mening
howev
caution
absenc
aforement
sign
exclud
central
nervou
system
involv
furthermor
suggest
evalu
infant
variou
foci
infect
acut
otiti
media
conjunct
osteomyel
pyogen
arthriti
skin
softtissu
infect
lo
arbitrarili
defin
infect
day
life
common
organ
isol
lo
includ
coagulaseneg
staphylococci
third
case
may
may
associ
medic
devic
yeast
candida
spp
infect
anoth
import
pathogen
also
increas
recognit
viral
respiratori
infect
possibl
caus
lo
common
clinic
find
includ
hypothermia
hyperglycemia
apnea
bradycardia
sever
factor
may
increas
risk
lo
significantli
infant
lo
indwel
central
vascular
cathet
time
infect
infant
eo
vs
p
addit
infant
lo
surgic
procedur
infect
vs
p
clinic
present
infect
may
overlap
noninfecti
caus
newborn
previous
demonstr
reli
symptom
alon
may
suffici
diagnos
neonat
infect
bacteremia
report
infant
without
clinic
sign
sepsi
sever
diagnost
test
principl
may
guid
clinician
evalu
infant
infect
aap
committe
fetu
newborn
publish
clinic
report
evalu
asymptomat
infant
week
gestat
risk
factor
sepsi
evalu
asymptomat
preterm
infant
risk
factor
sepsi
shown
fig
similar
algorithm
evalu
asymptomat
term
infant
week
gestat
avail
aap
committe
fetu
newborn
http
addit
principl
evalu
infant
risk
factor
sepsi
follow
major
risk
factor
neonat
sepsi
includ
chorioamnion
prolong
ruptur
membran
hour
colon
gb
inadequ
intrapartum
antimicrobi
prophylaxi
iap
chorioamnion
usual
present
matern
fever
greater
c
f
diagnosi
discuss
obstetr
provid
matern
fever
may
abnorm
find
chorioamnion
adequ
iap
mean
matern
treatment
penicillin
ampicillin
cefazolin
earlier
hour
deliveri
least
ml
blood
may
suffici
singl
blood
cultur
peripher
vein
blood
cultur
umbil
arteri
cathet
umbil
vein
may
reliabl
altern
follow
asept
techniqu
screen
blood
cultur
proven
valu
recommend
complet
blood
count
differenti
poor
posit
predict
valu
suggest
wait
hour
birth
avoid
fals
normal
valu
birth
platelet
count
remain
low
day
week
sepsi
thu
use
follow
respons
treatment
sensit
creactiv
protein
crp
improv
done
hour
birth
bacteri
sepsi
unlik
crp
remain
normal
lumbar
punctur
may
indic
infant
sepsi
highli
suspect
infant
bacteremia
infant
fail
respond
antimicrobi
therapi
urinari
tract
infect
newborn
associ
episod
bacteremia
thu
urin
cultur
part
routin
sepsi
workup
microbiolog
evalu
use
gastric
aspir
tracheal
aspir
superfici
bodi
site
cultur
limit
valu
routin
recommend
sepsi
sever
acutephas
reactant
biomark
neutrophil
procalcitonin
pct
crp
may
use
adjunct
evalu
manag
neonat
infect
diagnost
use
variou
surrog
marker
depend
phase
neonat
sepsi
earli
phase
hour
mid
phase
hour
pct
late
phase
greater
hour
crp
highaffin
fc
receptor
increas
exposur
bacteri
fungal
agent
use
relat
high
neg
predict
valu
well
decreas
concentr
serial
determin
infant
undergo
antimicrobi
treatment
bacteremia
howev
scarciti
medic
evid
recommend
routin
evalu
neonat
infect
may
readili
avail
procalcitonin
releas
tissu
increas
infect
around
hour
peak
hour
may
also
increas
noninfecti
caus
respiratori
distress
syndrom
physiolog
increas
first
hour
birth
pct
may
readili
avail
turnaround
time
vari
differ
institut
minut
hour
crp
increas
around
hour
associ
inflammatori
respons
releas
peak
hour
crp
use
algorithmbas
guidelin
aap
committe
fetu
newborn
evalu
asymptomat
term
preterm
infant
risk
factor
sepsi
best
use
part
group
diagnost
test
togeth
blood
cultur
white
blood
cell
differenti
evalu
neonat
infect
howev
enough
medic
evid
time
recommend
serial
determin
crp
guid
durat
antimicrobi
therapi
infant
studi
need
evalu
use
sequenti
determin
crp
biomark
antimicrobi
stewardship
program
asp
nicu
set
infecti
diseas
societi
america
collabor
american
societi
microbiolog
affirm
import
close
collabor
posit
work
relationship
clinician
microbiologist
better
serv
patient
uptod
edit
red
book
provid
contact
inform
expert
advic
nation
collabor
studi
group
give
guidanc
diagnost
assay
regard
specif
agent
caus
mothertochild
transmiss
import
know
variou
microbiolog
resourc
avail
local
includ
limit
pcr
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
rapid
antigen
test
respiratori
virus
may
lack
sensit
import
nicu
set
control
local
outbreak
sever
nucleic
acid
amplif
test
platform
current
avail
differ
number
analyt
detect
import
obtain
adequ
specimen
use
suitabl
viral
transport
media
follow
manufactur
instruct
malditof
valuabl
altern
convent
microbiolog
assay
howev
may
readili
avail
resourc
diagnost
test
institut
howev
avail
sever
practic
applic
may
benefit
clinic
manag
even
nicu
set
earlier
accur
diagnosi
neonat
sepsi
due
variou
bacteria
rapid
identif
highli
virul
gb
caus
mening
lo
infant
identif
maternaltochild
transmiss
chorioamnion
neonat
infect
opportunist
pathogen
accur
identif
bloodstream
infect
associ
fungal
infect
nicu
identif
monitor
spread
nosocomi
outbreak
eg
methicillinresist
staphylococcu
aureu
mrsa
candida
parapsilosi
nicu
appropri
specimen
diagnost
evalu
collect
clinic
stabl
patient
empir
antimicrobi
therapi
initi
neonat
sepsi
recommend
discuss
complic
case
multidrug
resist
organ
infant
improv
therapi
requir
unconvent
dose
regimen
antimicrobi
agent
pediatr
infecti
diseas
specialist
ampicillin
gentamicin
remain
cornerston
initi
antimicrobi
regimen
earlyonset
neonat
infect
combin
broadspectrum
antibiot
regimen
cover
common
caus
gb
e
coli
eo
synergist
activ
gb
listeria
monocytogen
dose
regimen
ampicillin
may
chang
time
base
chronolog
age
infant
bodi
weight
exampl
infant
weigh
greater
g
may
need
dose
adjust
ampicillin
mgkgd
intraven
iv
divid
everi
hour
mgkgd
iv
divid
everi
hour
oncedaili
dose
gentamicin
mgkg
iv
qd
use
term
newborn
decad
pharmacodynam
characterist
aminoglycosid
allow
use
oncedaili
dose
includ
concentrationdepend
kill
peak
concentr
minim
inhibitori
concentr
peakmic
ratio
postantibiot
effect
leukocyt
enhanc
prevent
adapt
resist
thirdgener
cephalosporin
use
judici
signific
associ
use
thirdgener
cephalosporin
invas
candidiasi
preterm
infant
cefotaxim
excel
penetr
cerebrospin
fluid
therapeut
use
limit
gramneg
mening
routin
use
cefotaxim
eo
may
lead
rapid
develop
drugresist
organ
ceftriaxon
contraind
neonat
reason
highli
protein
bound
may
displac
bilirubin
progress
hyperbilirubinemia
concurr
administr
calciumcontain
solut
may
produc
insolubl
precipit
ceftriaxonecalcium
salt
lead
cardiorespiratori
complic
aap
period
updat
dose
regimen
recommend
therapi
select
neonat
infect
nelson
pediatr
antimicrobi
therapi
provid
variou
antimicrobi
regimen
antibiot
antivir
antifung
agent
base
bodi
weight
infant
chronolog
age
gestat
postnat
age
new
edit
monthli
updat
short
interest
report
relat
pediatr
antimicrobi
therapi
post
wwwaaporgenusaapstorenelson
pageswhatsnewaspx
suggest
durat
antibiot
therapi
eo
adapt
nelson
pediatr
antimicrobi
therapi
aap
committe
fetu
newborn
shown
tabl
sever
antivir
agent
use
treatment
neonat
viral
infect
acyclovir
mgkgd
iv
divid
everi
hour
treatment
choic
term
infant
herp
simplex
viru
hsv
varicellazost
infect
sever
topic
agent
ganciclovir
ophthalm
gel
iododeoxyuridin
trifluridin
may
ad
system
antivir
regimen
eye
involv
parenter
therapi
acyclovir
recommend
give
hsv
suppress
regimen
mgm
dose
po
tid
improv
neurodevelopment
outcom
infant
central
nervou
system
involv
current
dose
regimen
valacyclovir
infant
younger
month
age
aap
committe
infecti
diseas
committe
fetu
newborn
recent
publish
algorithmbas
guidelin
evalu
treatment
asymptomat
infant
born
mother
activ
herp
lesion
http
oral
valganciclovir
mgkgdose
po
bid
drug
choic
infant
symptomat
congenit
cytomegaloviru
cmv
diseas
without
central
nervou
system
involv
treatment
congenit
cmv
initi
first
month
life
kimberlin
colleagu
conclud
phase
iii
random
doubleblind
placebocontrol
multin
studi
month
valganciclovir
regimen
symptomat
congenit
cmv
diseas
significantli
improv
hear
neurodevelopment
outcom
signific
improv
languag
recept
commun
year
age
less
grade
neutropenia
week
oral
valganciclovir
compar
week
iv
ganciclovir
report
previous
iv
ganciclovir
mgkgdose
bid
use
initi
infant
symptomat
congenit
cmv
diseas
oral
valganciclovir
contraind
due
extrem
prematur
nec
dose
regimen
treatment
choic
perinat
postnat
acquir
cmv
diseas
associ
enceph
hepat
pneumon
persist
thrombocytopenia
oral
oseltamivir
mgkgdose
bid
remain
treatment
choic
term
infant
influenza
infect
oral
suspens
formul
avail
mgml
offer
young
infant
suspect
confirm
influenza
infect
regardless
sever
higher
risk
complic
limit
data
avail
weightbas
dose
regimen
preterm
infant
use
postmenstru
age
ie
gestat
age
plu
chronolog
age
less
week
postmenstru
age
mgkgdose
po
bid
week
mgkgdose
po
bid
greater
week
mgkgdose
po
bid
current
dose
regimen
inhal
zanamivir
young
infant
suggest
durat
antivir
therapi
prophylaxi
suppress
regimen
congenit
perinat
postnat
acquir
viral
infect
adapt
nelson
pediatr
antimicrobi
therapi
aap
committe
infecti
diseas
committe
fetu
newborn
shown
tabl
fig
show
extens
cutan
aspergillosi
preterm
infant
poor
surgic
risk
success
treat
combin
antifung
agent
fluconazol
prophylaxi
mgkgd
twice
week
may
indic
highrisk
infant
birth
weight
less
g
institut
high
incid
candidiasi
ie
fluconazol
prophylaxi
mgkg
weekli
may
offer
young
infant
younger
month
old
extracorpor
membran
oxygen
suggest
durat
antifung
treatment
candidiasi
aspergillosi
adapt
nelson
pediatr
antimicrobi
therapi
shown
tabl
surgic
intervent
may
indic
sourc
control
neonat
infect
singlecent
retrospect
studi
necassoci
blood
stream
infect
bsi
occur
within
day
nec
diagnosi
note
approxim
infant
one
episod
bsi
infant
necassoci
bsi
higher
odd
adjust
odd
ratio
ci
surgic
intervent
compar
without
bsi
utmost
import
correspond
pediatr
surgeri
regard
sourc
control
infect
clinic
indic
necassoci
bsi
higher
odd
death
adjust
odd
ratio
ci
follow
includ
diseasespecif
condit
may
requir
surgic
intervent
adequ
sourc
control
infect
infant
clinic
stabl
pediatr
provid
encourag
discuss
surgic
colleagu
follow
surgic
treatment
option
earli
debrid
cutan
lesion
dissemin
aspergillosi
surgic
drainag
periton
bowel
ruptur
wound
clean
debrid
rapidli
spread
cellul
aureu
necrot
fasciiti
group
b
streptococci
tetanu
neonatorum
surgic
drainag
pu
osteomyel
suppur
arthriti
thoracostomi
drainag
empyema
surgic
drainag
breast
abscess
may
need
minim
damag
breast
tissu
surgic
intervent
primari
diseas
infant
may
also
increas
risk
neonat
infect
higher
rate
surgic
site
infect
defin
superfici
deep
organ
infect
within
day
surgic
procedur
note
among
infant
follow
closur
gastroschisi
import
close
monitor
infant
surgic
site
infect
requir
significantli
longer
hospit
stay
variou
measur
use
depend
avail
local
resourc
prevent
neonat
infect
includ
limit
gb
prophylaxi
hand
hygien
immun
immunoprophylaxi
asp
probiot
prebiot
care
bundl
iap
prevent
strategi
substanti
reduc
incid
earlyonset
gb
follow
indic
iap
previou
infant
invas
gb
diseas
gb
bacteriuria
current
pregnanc
posit
gb
vaginalrect
screen
week
gestat
except
cesarean
deliveri
without
labor
ruptur
membran
unknown
matern
gb
statu
deliveri
less
week
ruptur
membran
hour
fever
equal
greater
f
c
adequ
iap
mean
receiv
penicillin
ampicillin
cefazolin
least
hour
deliveri
cefazolin
may
use
nonseri
blactam
allergi
histori
seriou
blactam
allergi
anaphylaxi
angioedema
respiratori
insuffici
urticari
rash
gb
isol
suscept
clindamycin
may
use
otherwis
vancomycin
altern
high
resist
rate
erythromycin
recommend
center
diseas
control
prevent
extens
onlin
resourc
gb
clinician
includ
algorithmbas
guidanc
secondari
prevent
eo
newborn
web
page
also
provid
applic
prevent
group
b
strep
includ
guidanc
variou
patient
scenario
collabor
differ
medic
societi
aap
american
colleg
obstetrician
gynecologist
http
wwwcdcgovgroupbstrepguidelinesindexhtml
doubt
hand
hygien
remain
cornerston
decreas
health
careassoci
infect
differ
hospit
set
includ
nicu
fact
variou
educ
program
multidisciplinari
qualityimprov
team
guidelin
proven
effect
hand
hygien
decreas
infect
howev
significantli
affect
complianc
center
diseas
control
prevent
web
site
http
wwwcdcgovhandhygien
contain
resourc
hand
hygien
health
care
set
includ
applic
iscrub
monitor
hand
hygien
complianc
use
iphon
ipod
touch
thu
hand
hygien
guidelin
effect
reduc
infect
use
soap
water
recommend
decontamin
visibl
soil
hand
rub
hand
togeth
vigor
second
alcoholbas
gel
foam
antisept
soap
may
use
routin
hand
hygien
grossli
contamin
hand
hygien
complianc
improv
avail
alcoholbas
product
infant
bedsid
antimicrobialimpregn
towelett
wipe
consid
altern
substitut
wash
soap
water
alcoholbas
gel
foam
develop
safe
effect
vaccin
arguabl
one
greatest
medic
intervent
last
centuri
hepat
b
vaccin
agent
unit
state
recommend
administ
birth
variou
brand
avail
unit
state
efficaci
prevent
hepat
b
viru
infect
diseas
addit
inform
regard
recommend
dosag
hepat
b
vaccin
avail
recent
edit
red
book
annual
public
advisori
committe
immun
practic
first
dose
primari
seri
subsequ
vaccin
diphtheria
tetanu
toxoid
acellular
pertussi
vaccin
dtap
haemophilu
influenza
type
b
inactiv
polio
pneumococc
rotaviru
vaccin
administ
minimum
age
week
care
giver
home
advis
import
immun
famili
member
protect
infant
young
vaccin
call
cocoon
prevent
vaccineprevent
diseas
pertussi
influenza
young
infant
educ
materi
cocoon
parent
clinician
avail
aap
web
site
http
cocooninghtml
octob
use
tetanu
toxoid
reduc
diphtheria
toxoid
acellular
pertussi
vaccin
tdap
everi
pregnanc
recommend
increas
case
pertussi
young
infant
recent
year
mother
protect
antibodi
pertussi
shortliv
dose
tdap
previou
pregnanc
may
protect
infant
subsequ
pregnanc
young
preterm
infant
year
age
born
week
gestat
receiv
palivizumab
rsv
season
immunoprophylaxi
five
monthli
dose
palivizumab
mgkg
given
intramuscularli
provid
adequ
protect
month
indic
rsv
season
includ
preterm
infant
year
age
born
week
gestat
chronic
lung
diseas
prematur
requir
greater
oxygen
least
first
day
life
young
infant
year
age
certain
hemodynam
signific
heart
diseas
clinician
consult
current
guidelin
polici
statement
aap
regard
palivizumab
prophylaxi
among
young
children
increas
risk
hospit
rsv
infect
injudici
use
antibiot
alter
neonat
microflora
increas
exposur
pressur
lead
antimicrobi
resist
nicu
milieu
intervent
permiss
develop
antibioticresist
organ
aap
committe
fetu
newborn
list
asp
strategi
may
use
nicu
set
base
guidelin
infecti
diseas
societi
america
societi
healthcar
epidemiolog
america
box
medic
evid
support
use
probiot
prevent
nec
preterm
infant
probiot
oral
supplement
contain
suffici
amount
viabl
microorgan
alter
host
microflora
potenti
health
benefit
metaanalysi
base
random
control
trial
involv
approxim
infant
born
week
gestat
andor
weigh
less
equal
g
birth
show
enter
use
probiot
significantli
decreas
incid
sever
nec
mortal
sever
advers
event
system
infect
directli
relat
probiot
use
report
aap
committe
nutrit
howev
recommend
use
probiot
young
infant
studi
done
resolv
problemat
issu
note
larg
heterogen
studi
includ
review
differ
mixtur
probiot
use
combin
probiot
use
studi
avail
unit
state
remain
gap
knowledg
probiot
bacteria
speci
use
microbi
dose
well
durat
administr
updat
review
aforement
metaanalysi
random
control
trial
continu
support
chang
practic
supplement
preterm
infant
probiot
review
provid
similar
result
involv
infant
probiot
significantli
reduc
sever
nec
mortal
howev
previous
mention
gap
knowledg
remain
well
need
compar
studi
scarciti
medic
evid
recommend
addit
prebiot
oligosaccharid
infant
formula
prebiot
nondigest
food
ingredi
occur
natur
dietari
supplement
enhanc
growth
probiot
bacteria
bifidobacterium
spp
sever
studi
report
addit
prebiot
infant
formula
significantli
increas
bifidobacteria
count
stool
without
advers
effect
note
howev
clinic
efficaci
well
costbenefit
analys
regard
addit
oligosaccharid
infant
formula
lack
infant
human
milk
remain
best
sourc
natur
occur
prebiot
probiot
immunoprotect
compound
known
decreas
incid
respiratori
gastrointestin
infect
nurseri
intens
care
unit
care
bundl
invas
procedur
may
increas
infant
risk
health
careassoci
infect
nicu
set
infect
includ
central
lineassoci
bsi
clabsi
pneumonia
skin
soft
tissu
infect
occasion
vaccineprevent
diseas
outbreak
respiratori
viral
infect
care
bundl
set
intervent
aim
reduc
health
careassoci
infect
nicu
common
caus
clabsi
lo
coagulaseneg
staphylococci
sever
random
clinic
trial
use
lowdos
vancomycin
parenter
solut
preterm
infant
show
signific
decreas
length
stay
mortal
antibioticlock
therapi
done
neonat
significantli
decreas
clabsi
howev
power
answer
whether
vancomycin
resist
occur
current
recommend
lack
longterm
efficaci
evid
well
concern
develop
drugresist
organ
infect
control
intend
decreas
clabsi
nicu
includ
measur
decreas
extralumin
intravascular
catheterrel
infect
variou
techniqu
guidelin
prevent
clabsi
infant
adapt
aap
committe
fetu
newborn
shown
box
specif
practic
may
adapt
local
set
prevent
vaccineprevent
diseas
outbreak
respiratori
viral
infect
includ
limit
vaccin
health
care
provid
influenza
pertussi
tdap
visit
guidelin
screen
ill
symptomat
visitor
cohort
case
cluster
infect
outbreak
situat
cohort
may
possibl
earli
screen
procedur
use
pcrbase
assay
place
avail
case
cluster
respiratori
viral
infect
appropri
isol
eg
contact
precaut
mrsa
droplet
precaut
influenza
airborn
precaut
measl
observ
infant
clean
umbil
insert
site
use
antisept
povidoneiodin
cathet
insert
avoid
use
topic
antibiot
ointment
cream
insert
site
prevent
fungal
infect
antimicrobi
resist
use
low
dose
heparin
uml
fluid
infus
umbil
arteri
cathet
remov
umbil
cathet
soon
longer
need
sign
vascular
insuffici
lower
extrem
umbil
arteri
access
present
may
replac
malfunct
umbil
arteri
cathet
left
place
day
umbil
venou
cathet
may
use
day
manag
asept
colon
infect
pathogen
requir
addit
protect
beyond
standard
precaut
neonat
infect
continu
caus
morbid
mortal
infant
gb
e
coli
common
agent
eo
wherea
coagulaseneg
staphylococcu
predomin
caus
lo
increas
recognit
respiratori
viral
infect
contribut
rule
sepsi
young
infant
whose
present
similar
bacteri
infect
blood
cultur
birth
white
blood
cell
without
crp
use
algorithmbas
guidelin
evalu
asymptomat
term
preterm
infant
risk
factor
sepsi
ampicillin
gentamicin
remain
cornerston
initi
antimicrobi
regimen
neonat
infect
thirdgener
cephalosporin
use
judici
use
antivir
acyclovir
ganciclovir
valganciclovir
oseltamivir
antifung
fluconazol
amphotericin
b
voriconazol
treatment
prophylact
regimen
may
reduc
mortal
morbid
specif
viral
fungal
diseas
infant
variou
strategi
gb
prophylaxi
hand
hygien
immun
immunoprophylaxi
asp
probiot
prebiot
nicu
care
bundl
may
use
prevent
infect
infant
